Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Transcription Factors as Therapeutic Targets II
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Transcription Factors as Therapeutic Targets II

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 11296

Special Issue Editor

Dr. Takaomi Sanda

E-Mail Website
Guest Editor
1. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Interests: transcription; transcription factor; enhancer; core regulatory circuit; stem cells; hematopoiesis; acute leukemia; T-cell acute lymphoblastic leukemia; oncogene; TAL1
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Deregulation of transcription factor genes are frequently observed in various human diseases.  Understanding the molecular pathogenesis as well as the development of therapeutic approaches are crucial to further advance the treatment outcome.  Although the feasibility of transcription factors as therapeutic targets has long been realized, the development of drugs is still very challenging due to several pharmacological and biological reasons.  Therefore, an improved knowledge is necessary to make transcription factors “actionable”. The second edition of this Special Issue aims to provide a forum for the dissemination of the latest information on new approaches and methods targeting transcription factors, and with methods of testing their success in cancer or other human diseases.

Dr. Takaomi Sanda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Transcription
  • Transcription factor
  • Enhancer
  • Epigenetics
  • Chromatin
  • Small-molecules
  • Cancer
  • Immunological diseases
  • Infectious diseases
  • Neuronal diseases

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 717 KiB  
Review
Tuning up Transcription Factors for Therapy
by Attila Becskei
Molecules 2020, 25(8), 1902; https://doi.org/10.3390/molecules25081902 - 20 Apr 2020
Cited by 8 | Viewed by 3987
Abstract
The recent developments in the delivery and design of transcription factors put their therapeutic applications within reach, exemplified by cell replacement, cancer differentiation and T-cell based cancer therapies. The success of such applications depends on the efficacy and precision in the action of [...] Read more.
The recent developments in the delivery and design of transcription factors put their therapeutic applications within reach, exemplified by cell replacement, cancer differentiation and T-cell based cancer therapies. The success of such applications depends on the efficacy and precision in the action of transcription factors. The biophysical and genetic characterization of the paradigmatic prokaryotic repressors, LacI and TetR and the designer transcription factors, transcription activator-like effector (TALE) and CRISPR-dCas9 revealed common principles behind their efficacy, which can aid the optimization of transcriptional activators and repressors. Further studies will be required to analyze the linkage between dissociation constants and enzymatic activity, the role of phase separation and squelching in activation and repression and the long-range interaction of transcription factors with epigenetic regulators in the context of the chromosomes. Understanding these mechanisms will help to tailor natural and synthetic transcription factors to the needs of specific applications. Full article
(This article belongs to the Special Issue Transcription Factors as Therapeutic Targets II)
►▼ Show Figures

Figure 1

28 pages, 1452 KiB  
Review
P-TEFb as A Promising Therapeutic Target
by Koh Fujinaga
Molecules 2020, 25(4), 838; https://doi.org/10.3390/molecules25040838 - 14 Feb 2020
Cited by 20 | Viewed by 6988
Abstract
The positive transcription elongation factor b (P-TEFb) was first identified as a general factor that stimulates transcription elongation by RNA polymerase II (RNAPII), but soon afterwards it turned out to be an essential cellular co-factor of human immunodeficiency virus (HIV) transcription mediated by [...] Read more.
The positive transcription elongation factor b (P-TEFb) was first identified as a general factor that stimulates transcription elongation by RNA polymerase II (RNAPII), but soon afterwards it turned out to be an essential cellular co-factor of human immunodeficiency virus (HIV) transcription mediated by viral Tat proteins. Studies on the mechanisms of Tat-dependent HIV transcription have led to radical advances in our knowledge regarding the mechanism of eukaryotic transcription, including the discoveries that P-TEFb-mediated elongation control of cellular transcription is a main regulatory step of gene expression in eukaryotes, and deregulation of P-TEFb activity plays critical roles in many human diseases and conditions in addition to HIV/AIDS. P-TEFb is now recognized as an attractive and promising therapeutic target for inflammation/autoimmune diseases, cardiac hypertrophy, cancer, infectious diseases, etc. In this review article, I will summarize our knowledge about basic P-TEFb functions, the regulatory mechanism of P-TEFb-dependent transcription, P-TEFb’s involvement in biological processes and diseases, and current approaches to manipulating P-TEFb functions for the treatment of these diseases. Full article
(This article belongs to the Special Issue Transcription Factors as Therapeutic Targets II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop